Abstracts

COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US

HIV Prevention Trials Network (HPTN) 083 demonstrated superior efficacy of long-acting injectable cabotegravir (CAB-LA) compared to oral tenofovir disoproxil fumarate/emtricitabine (F/TDF) for HIV pre-exposure prophylaxis (PrEP). CAB-LA cost may be higher than that of generic F/TDF. We projected the clinical benefit of CAB-LA vs. F/TDF and estimated the cost at which CAB-LA would be cost-effective.…

ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR

Lenacapavir (LEN) in vitro resistance selections identified resistance associated mutations (RAMs) in HIV-1 capsid (CA) associated with reduced susceptibility (L56I, M66I, Q67H, K70N, N74D, N74S, and T107N). Characterization of mutants in single-cycle (SC) assays indicated that most of these RAMs were associated with reduced replication capacity (RC). We studied LEN antiviral activity in isolates containing…

A CLUSTER RANDOMIZED TRIAL OF CONTACT TRACING IN HOUSEHOLDS OF INDEX PATIENTS WITH TB

Household contact tracing and investigation for tuberculosis (TB) is recommended, but has not been widely implemented in high HIV-prevalence settings due to uncertainty over effectiveness and the costs of conducting home visits. Intensive HIV/TB screening with appropriate action could reduce household TB transmission and mortality. Index TB patients in two health districts of South Africa…

HEPATOCELLULAR CARCINOMA AND HBV VIREMIA IN HIV/HBV-COINFECTED PERSONS IN NA-ACCORD

Chronic hepatitis B (HBV) is the predominant cause of hepatocellular carcinoma (HCC) worldwide. Although HBV coinfection is common in HIV, the determinants of HCC in HIV/HBV coinfection are poorly characterized. We examined the incidence and predictors of HCC in a multi-cohort study of HIV/HBV-coinfected individuals. We examined all HIV/HBV-coinfected persons (defined by positive HBV surface…

UPRISING CIRCULATION OF HBV-COMPLEX PROFILES WITH HBsAg VACCINE-ESCAPE MUTATIONS

Vaccine-escape mutations can alter HBsAg recognition by antibodies thus challenging vaccine efficacy, promoting immunosuppression-driven HBV-reactivation and impairing HBsAg detection by immunoassays. Limited information is available on the circulation of vaccine-escape mutations, single or in complex mutational profiles, over time and their impact on serological parameters in the setting of HBV genotype-D. This study includes HBsAg…